Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-22

Clinical Trial Update: Ropeginterferon for Treatment Free Remission [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Ropeginterferon alfa-2b for treatment-free remission in chronic myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ropeginterferon alfa-2b (ropeginterferon alfa-2b)

Snippet

Sponsor: Dong-Wook Kim | Conditions: CML (Chronic Myelogenous Leukemia) | Phase 4 | Status: COMPLETED